Literature DB >> 18633675

Therapeutic potential of two probiotics in inflammatory bowel disease as observed in the trinitrobenzene sulfonic acid model of colitis.

Einat Amit-Romach1, Zehava Uni, Ram Reifen.   

Abstract

PURPOSE: The pathogenesis of inflammatory bowel disease is thought to be a multifactorial process. One of the leading hypotheses is that an imbalance in normal gut flora induces an excessive immune response and contributes to inflammation in the gastrointestinal tract. Administration of probiotic bacteria reduces symptoms in patients suffering from inflammatory bowel diseases, probably via both manipulation of the microflora and stimulation of the intestinal immune system. In the current study the therapeutic potential of two different probiotics-Lactobacillus GG and a mixture of Streptococcus thermophilus, Lactobacillus acidophilus, and Bifidobacterium longum (YO-MIX Y 109 FRO 1000)--in a rat model of colitis were evaluated.
METHODS: Male Wistar rats were administered probiotics for three days simultaneously with colitis induction. Colonic damage was evaluated histologically and biochemically and colonic tissues, as well as fecal samples, were used for bacterial studies using 16S rRNA gene primers.
RESULTS: Probiotics administration reduced the relative amounts of the pathogenic bacteria Aeromonas and Escherichia coli in the colonic tissue. However, whereas both probiotics affected colon morphology, only Lactobacillus GG administration reduced myeloperoxidase activity.
CONCLUSIONS: We report the therapeutic rather than preventive potential of two different probiotics in an animal model of colitis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18633675     DOI: 10.1007/s10350-008-9394-1

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  7 in total

1.  Effects of a Lactobacillus reuteri BR11 mutant deficient in the cystine-transport system in a rat model of inflammatory bowel disease.

Authors:  Haydn L Atkins; Mark S Geier; Luca D Prisciandaro; Ashok K Pattanaik; Rebecca E A Forder; Mark S Turner; Gordon S Howarth
Journal:  Dig Dis Sci       Date:  2011-10-26       Impact factor: 3.199

2.  The insect peptide coprisin prevents Clostridium difficile-mediated acute inflammation and mucosal damage through selective antimicrobial activity.

Authors:  Jin Ku Kang; Jae Sam Hwang; Hyo Jung Nam; Keun Jae Ahn; Heon Seok; Sung-Kuk Kim; Eun Young Yun; Charalabos Pothoulakis; John Thomas Lamont; Ho Kim
Journal:  Antimicrob Agents Chemother       Date:  2011-08-01       Impact factor: 5.191

3.  The Prebiotic Effect of Australian Seaweeds on Commensal Bacteria and Short Chain Fatty Acid Production in a Simulated Gut Model.

Authors:  Emer Shannon; Michael Conlon; Maria Hayes
Journal:  Nutrients       Date:  2022-05-23       Impact factor: 6.706

4.  Comparison of the immunomodulatory properties of three probiotic strains of Lactobacilli using complex culture systems: prediction for in vivo efficacy.

Authors:  Erika Mileti; Gianluca Matteoli; Iliyan D Iliev; Maria Rescigno
Journal:  PLoS One       Date:  2009-09-16       Impact factor: 3.240

5.  Lactobacillus paracasei reduces intestinal inflammation in adoptive transfer mouse model of experimental colitis.

Authors:  Manuel Oliveira; Nabil Bosco; Genevieve Perruisseau; Jeanne Nicolas; Iris Segura-Roggero; Stéphane Duboux; Muriel Briand; Stéphanie Blum; Jalil Benyacoub
Journal:  Clin Dev Immunol       Date:  2011-07-25

6.  Early Gut Microbiota Intervention Suppresses DSS-Induced Inflammatory Responses by Deactivating TLR/NLR Signalling in Pigs.

Authors:  Yi Xiao; Honglin Yan; Hui Diao; Bing Yu; Jun He; Jie Yu; Ping Zheng; Xiangbing Mao; Yuheng Luo; Daiwen Chen
Journal:  Sci Rep       Date:  2017-06-12       Impact factor: 4.379

7.  Prospective study of probiotic supplementation results in immune stimulation and improvement of upper respiratory infection rate.

Authors:  Hong Zhang; Chiajung Yeh; Zonglian Jin; Liwei Ding; Bryan Y Liu; Li Zhang; H Kathleen Dannelly
Journal:  Synth Syst Biotechnol       Date:  2018-03-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.